although a high rate of microaneurysm formation alone has been shown to be a biomarker for the later development of clinically significant macular edema (CSME). [195] Microaneurysms are also found ...

The following is a summary of “Cystoid Macular Edema Following Rhegmatogenous Retinal Detachment Repair Surgery: Incidence, ...

Diabetic macular edema remains an important cause of vision loss among ... As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is being assessed in pivotal Phase 3 clinical trials to enhance the efficacy of standard anti-VEGF-A therapies.

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant to treat diabetic macular edema (DME). 1 In clinical trials, patients with DME who ...

Despite meeting primary and secondary endpoints, the stock experienced a significant drop. The clinical trial ... for patients with Diabetic Macular Edema (DME). DURAVYU 2.7mg showed a +7.1 ...